기간별 수익률
시세
밸류에이션
일정 · 전망
| 항목 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 매출 | 28.5B | 34.1B | 45.0B | 65.2B |
| 영업이익 | 8.7B | 10.8B | 17.0B | 29.7B |
| 영업이익률 | 30.3% | 31.6% | 37.8% | 45.6% |
| 순이익 | 6.2B | 5.2B | 10.6B | 20.6B |
| 순이익률 | 21.9% | 15.4% | 23.5% | 31.7% |
| 평가사 | 의견 | 날짜 |
|---|---|---|
| 애널리스트 상세 데이터가 없습니다. | ||
| 의원 | 구분 | 신고 규모 | 공시일 |
|---|---|---|---|
| R. Khanna 하원 | 매수 | $1K-$15K | 2026-10-09 거래 09-04 |
| J. Boozman 상원 | 매도 | $1K-$15K | 2026-08-24 거래 2025-11-21 |
| G. Cisneros 하원 | 매수 | $50K-$100K | 2026-07-03 거래 06-10 |
앱에서 의원 거래 확인하기
QR 스캔하여 앱 설치
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.